Notice ID: a2b5470efb094112bde07eeb592d9a8bCombined Synopsis/Solicitation
cGMP Mitragynine HCl Supplemental Stability & Analytical Activities
Archived on August 30, 2024. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM UTC−04:00
- Posted
- August 7, 2024
- Notice type
- Combined Synopsis/Solicitation
- NAICS
- 541380: Testing Laboratories and Services
- Agency
- Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH
Notice details
- Office
- NATIONAL INSTITUTES OF HEALTH NIDA
- Place of performance
- Albany, NY, 12203
- Last updated
- Dec 4, 2025
Identifiers
- Solicitation number
- 75N95024Q00480
- Notice ID
- a2b5470efb094112bde07eeb592d9a8b
Description
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number is 75N95024Q00480 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures; and FAR Part 12 Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Curia Global, Inc., 26 Corporate Circle Albany, New York 12203 for cGMP Mitragynine HCl Supplemental Stability & Analytical Activities. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1). The Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS) is conducting a preclinical development of Mitragynine (MG) to support its clinical evaluation, as part of the Helping to End Addiction Long-term initiative (HEAL). The Contractor shall provide long term stability studies on two cGMP batches of Mitragynine HCl and requalify cGMP reference standard of Mitragynine HCl annually for up to 3 years. See Attachment 1 - Statement of Work.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Documents
No documents available.
Lifecycle
Solicitation:
75N95024Q00480- Combined Synopsis
- Combined SynopsisCurrentAug 7, 2024
cGMP Mitragynine HCl Supplemental Stability & Analytical Activities
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
75N95024Q00480
Archive Date
Aug 30, 2024
Office Address
Bethesda, MD, 20892